Paul Nathan, MBBS, PhD, FRCP, highlighted the favorable 5-year OS results of tebentafusp for patients with HLA-A*02:01–positive uveal melanoma.
Paul Nathan, MBBS, PhD, MCRP
Advertisement
Articles by Paul Nathan, MBBS, PhD, MCRP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
EC Expands Enfortumab Vedotin/Pembrolizumab Approval for Resectable MIBC
2
Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer
3
Which Head and Neck Cancer Data Should You Watch For at ESMO 2026?
4
Sofetabart Mipitecan Shows Activity Across FRα Expression Levels in PROC
5